Last reviewed · How we verify
Cisplatin / Carboplatin，Gemcitabine，Cindilimab
This is a combination regimen of platinum-based chemotherapy agents (cisplatin/carboplatin) and a nucleoside analog (gemcitabine), plus an anti-PD-L1 monoclonal antibody (cindilimab) that together kill cancer cells through DNA damage and immune checkpoint inhibition.
This is a combination regimen of platinum-based chemotherapy agents (cisplatin/carboplatin) and a nucleoside analog (gemcitabine), plus an anti-PD-L1 monoclonal antibody (cindilimab) that together kill cancer cells through DNA damage and immune checkpoint inhibition. Used for Non-small cell lung cancer, Other solid tumors (specific indications not fully characterized in available literature).
At a glance
| Generic name | Cisplatin / Carboplatin，Gemcitabine，Cindilimab |
|---|---|
| Sponsor | People's Hospital of Quzhou |
| Drug class | Combination chemotherapy with immune checkpoint inhibitor |
| Target | DNA (platinum agents, gemcitabine); PD-L1 (cindilimab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Cisplatin and carboplatin are platinum compounds that cross-link DNA and induce apoptosis in rapidly dividing cells. Gemcitabine is a deoxycytidine analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination. Cindilimab is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby restoring anti-tumor immune responses.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (specific indications not fully characterized in available literature)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Nephrotoxicity
- Neuropathy
- Immune-related adverse events (from cindilimab)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: